Johnson & Johnson's Janssen unit is recalling approximately
13,500 bottles of its top-selling anticoagulant Xarelto because of microbial
contamination discovered in a sample.
According to a recall notice in an FDA Enforcement Report,
the drug manufacturer said that it confirmed that a sales sample of the drug
was contaminated after a customer complaint, and so initiated a nationwide,
voluntary recall. The company reported that the product came from a plant in Puerto
Rico. The plant was among four on the island that J&J slated two years ago
for $225 million in upgrades.
To view the notice, click on the link below:
Xarelto came to market in the U.S. three years ago behind Boehringer Ingelheim's Pradaxa, but which has since eclipsed
it in sales. Like Pradaxa, Xarelto has come under scrutiny based on accusations
that the drug causes bleed outs and deaths. Lawsuits have been filed against
the manufacturer across the country, and a motion has been filed to consolidate
cases into an MDL.
Pittman, Dutton & Hellums, P.C., is currently
investigating Xarelto cases. If you or a loved one were prescribed Xarelto and
suffered an irreversible internal bleeding that lead to hospitalization and/or
death, contact Booth Samuels at toll free 1-866-515-8880 or by email at booths@pittmanudutton.com.
